marketbeat.com

Gilead Sciences Upgraded to Strong-Buy After Wall Street Rating Change

Gilead Sciences logoGilead Sciences
Sig0.90Sen+2.40Env0.00Soc0.00Gov0.00

Zacks Research upgraded Gilead Sciences from a hold rating to a strong-buy rating, lifting its stance versus the moderate-buy consensus. MarketBeat data show an average rating of Moderate Buy and a $158.04 price target. The stock fell 0.2%. The report also cited the latest earnings period and analysts’ expected EPS of -0.48 for the year, alongside disclosed shareholding changes by investors and a director.

Coverage (1)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro